Who are Estrogen Antagonists's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inluriyo, Orserdu, FULVESTRANT, Faslodex, E2 patch/antagonist, Tamoxifen, Letrozole, Anastrozole or Exemestane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/estrogen-antagonists.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Estrogen Antagonists — Competitive Intelligence Brief

Estrogen Antagonists (Estrogen Antagonists) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen receptor antagonist. Area: Oncology.

phase 3 Estrogen receptor antagonist Estrogen receptor (ER-α, ER-β) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Estrogen Antagonists (Estrogen Antagonists) — Alliance for Clinical Trials in Oncology. Estrogen antagonists block the activity of estrogen receptors to inhibit estrogen-driven cell growth, particularly in hormone-sensitive cancers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Estrogen Antagonists TARGET	Estrogen Antagonists	Alliance for Clinical Trials in Oncology	phase 3	Estrogen receptor antagonist	Estrogen receptor (ER-α, ER-β)
Inluriyo	IMLUNESTRANT	Eli Lilly And Co	marketed	Estrogen Receptor Antagonist [EPC]		2025-01-01
Orserdu	ELACESTRANT	Stemline Therap	marketed	Estrogen Receptor Antagonist [EPC]	Estrogen receptor	2023-01-01
FULVESTRANT	FULVESTRANT		marketed	Estrogen Receptor Antagonist [EPC]		2002-01-01
Faslodex	fulvestrant	AstraZeneca	marketed	Estrogen Receptor Antagonist [EPC]	Progesterone receptor	2002-01-01
E2 patch/antagonist	E2 patch/antagonist	Weill Medical College of Cornell University	marketed	Estrogen receptor antagonist / hormone replacement therapy	Estrogen receptor (ER-α, ER-β)
Tamoxifen, Letrozole, Anastrozole or Exemestane	Tamoxifen, Letrozole, Anastrozole or Exemestane	Institut Claudius Regaud	marketed	Estrogen receptor antagonist (tamoxifen); Aromatase inhibitor (letrozole, anastrozole, exemestane)	Estrogen receptor alpha (tamoxifen); Aromatase/CYP19A1 (letrozole, anastrozole, exemestane)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-02-14 — Faslodex · 9833459 · Formulation · US
2034-02-14 — Faslodex · 10188663 · Formulation · US
2034-05-17 — Faslodex · 9271990 · Formulation · US

Sponsor landscape (Estrogen receptor antagonist class)

Alliance for Clinical Trials in Oncology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Estrogen Antagonists — Competitive Intelligence Brief. https://druglandscape.com/ci/estrogen-antagonists. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab